Comparision of different dose of clopedogrel plus aspirin and aspirin alone for patients with drug-eluting stent implanting one year later: a prospective,randomized, multicenter, observation study

Comparision of different dose of clopedogrel plus aspirin and aspirin alone for patients with drug-eluting stent implanting one year later: a prospective randomized, multicenter, observation study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001249

Enrollment

Unknown

Registered

2011-01-09

Start date

2009-11-24

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease

Interventions

A:aspirin 100mg per day plus clopidogrel 25mg per day

B:aspirin 100mg per day plus clopidogrel 50mg per day

C:aspirin 100mg per day plus clopidogrel 275mg per day

D:aspirin 100mg per day plus clopidogrel 275mg per day

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Provide written informed consent and obey the study protocol; 2. Age >=18 years; 3. Patients ongoing coronary drug-eluting stent implantation one year ago.

Exclusion criteria

Exclusion criteria: 1. Allergic to aspirin or clopidogrel; 2. Patients with active bleeding; 3. Patients with bleeding diathesis; 4. Pregnancy; 5. Severe liver or renal function insufficiency; 6. Malignancies with life expectancy less than 1 year; 7. Hop up or excessive drinking; 8. Clotting time >1.5 the upper limit of normal (ULN); 9. Haematocrit <30%

Design outcomes

Primary

Measure	Time frame
Cardiovascular death, myocardial infarction, or stroke;	—

Secondary

Measure	Time frame
Recurrent ischemia, revascularization,heart falire,TIA and TIMI bleeding;	—

Countries

China

Contacts

Public ContactNing Tan

tanning100@126.com+86 13903073651

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026